Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-18 of 18 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
Koutsoumpli G, Stasiukonyte N, Hoogeboom BN, Daemen T
Vaccine, 42(22):126032, 03 Jul 2024
Cited by: 0 articles | PMID: 38964950
Add to export list
Oncolytic alphavirus replicons mediated recruitment and activation of T cells.
Bhatt DK, Meuleman SL, Hoogeboom BN, Daemen T
iScience, 27(3):109253, 16 Feb 2024
Cited by: 0 articles | PMID: 38425844 | PMCID: PMC10904282
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.
Komdeur FL, Singh A, van de Wall S, Meulenberg JJM, Boerma A, Hoogeboom BN, Paijens ST, Oyarce C, de Bruyn M, Schuuring E, Regts J, Marra R, Werner N, Sluis J, van der Zee AGJ, Wilschut JC, Allersma DP, van Zanten CJ, Kosterink JGW, [...] Daemen T
Mol Ther, 29(2):611-625, 05 Nov 2020
Cited by: 37 articles | PMID: 33160073 | PMCID: PMC7854293
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?
Koutsoumpli G, Ip PP, Schepel I, Hoogeboom BN, Boerma A, Daemen T
Ther Adv Vaccines Immunother, 7:2515135519874677, 03 Oct 2019
Cited by: 5 articles | PMID: 31620673 | PMCID: PMC6777054
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.
Draghiciu O, Nijman HW, Hoogeboom BN, Meijerhof T, Daemen T
Oncoimmunology, 4(3):e989764, 07 Jan 2015
Cited by: 69 articles | PMID: 25949902 | PMCID: PMC4404834
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.
Draghiciu O, Boerma A, Hoogeboom BN, Nijman HW, Daemen T
Oncoimmunology, 4(10):e1029699, 27 May 2015
Cited by: 19 articles | PMID: 26451295 | PMCID: PMC4589062
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7.
van de Wall S, Walczak M, van Rooij N, Hoogeboom BN, Meijerhof T, Nijman HW, Daemen T
Vaccines (Basel), 3(2):221-238, 24 Mar 2015
Cited by: 9 articles | PMID: 26343186 | PMCID: PMC4494346
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
P59. Depleting the suppressors for the benefit of immunotherapy against cervical cancer
Draghiciu O, Hoogeboom B, Meijerhof T, Nijman H, Daemen C
J Immunother Cancer, 2(suppl 2):P33-P33, 01 Jan 2014
Cited by: 0 articles | PMCID: PMC4072153
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.
Draghiciu O, Walczak M, Hoogeboom BN, Franken KL, Melief KJ, Nijman HW, Daemen T
Int J Cancer, 134(4):859-872, 04 Sep 2013
Cited by: 30 articles | PMID: 23922012
Add to export list
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, Molmans BH, Hollema H, Bart J, Drijfhout JW, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW
Int J Cancer, 131(5):E670-80, 31 Jan 2012
Cited by: 58 articles | PMID: 22139992
Add to export list
Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
Leffers N, Vermeij R, Hoogeboom BN, Schulze UR, Wolf R, Hamming IE, van der Zee AG, Melief KJ, van der Burg SH, Daemen T, Nijman HW
Int J Cancer, 130(1):105-112, 09 May 2011
Cited by: 35 articles | PMID: 21328579
Add to export list
Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.
Walczak M, de Mare A, Riezebos-Brilman A, Regts J, Hoogeboom BN, Visser JT, Fiedler M, Jansen-Dürr P, van der Zee AG, Nijman HW, Wilschut J, Daemen T
Mol Pharm, 8(1):65-77, 23 Sep 2010
Cited by: 12 articles | PMID: 20825215
Add to export list
Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens.
Lambeck AJ, Nijman HW, Hoogeboom BN, Regts J, de Mare A, Wilschut J, Daemen T
Vaccine, 28(26):4275-4282, 29 Apr 2010
Cited by: 9 articles | PMID: 20434555
Add to export list
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW
Int J Cancer, 125(9):2104-2113, 01 Nov 2009
Cited by: 81 articles | PMID: 19621448
Add to export list
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW
Cancer Immunol Immunother, 58(3):449-459, 13 Sep 2008
Cited by: 257 articles | PMID: 18791714 | PMCID: PMC11030692
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H
Int J Cancer, 121(3):606-614, 01 Aug 2007
Cited by: 25 articles | PMID: 17415711
Add to export list
Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.
Visser J, van Baarle D, Hoogeboom BN, Reesink N, Klip H, Schuuring E, Nijhuis E, Pawlita M, Bungener L, de Vries-Idema J, Nijman H, Miedema F, Daemen T, van der Zee A
Int J Cancer, 118(10):2529-2537, 01 May 2006
Cited by: 11 articles | PMID: 16353143
Add to export list
HLA class I alleles and cervical neoplasia.
Visser JT, Hoogeboom BN, Reesink-Peters N, Klip H, Hepkema B, van Velde H, van der Zee AG, Daemen T
J Infect Dis, 187(10):1675-1676, 01 May 2003
Cited by: 3 articles | PMID: 12721951
Add to export list

1-18 of 18 results

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Partnerships & funding